circRNA basic information
circBase ID: -
Name: hsa_circ_CDYL
Synonym: Circ-CDYL
Host Gene: CDYL
Genomic location(hg19): -
Genomic location(hg38): -
Subcellular localization: nucleus and cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0007256
MONDO name: hepatocellular carcinoma
Disease details: hepatocellular carcinoma / HCC
Disease DO ID:
 684, 686
Disease MeSH ID:
 D006528
Disease NCIt ID:
 C3099
Disease ICD11 ID:
 1294035808
Disease OMIM ID:
 114550
Species: Human
Species details: Homo sapiens
Tissue specimen:

HCC tissues; matched non-tumorous adjacent tissues; tumor tissues; para-carcinoma tissues
Cell lines:

HCCLM3; SMMC-7721; PLC/PRF/5; L02; QSG-7701; THP-1; U-937; 297T; HEK293T
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: HDGF, HIF1AN, NCL, NOTCH2, PI3K, AKT, mTORC1, P70 S6K, GSK3beta, beta-Catenin, C-MYC, SURVIVIN, BIRC5
Associated microRNA: miR-892a, miR-328-3p
Biological function: Circ-CDYL promotes malignant proliferation, self-renewal, chemoresistance, tumorigenesis, tumor growth, and EPCAM-positive liver tumor-initiating cell/stem-like properties in early HCC.
Molecular mechanism: Circ-CDYL acts as a ceRNA/microRNA sponge for miR-892a and miR-328-3p to regulate HDGF and HIF1AN, thereby activating HDGF-NCL-PI3K-AKT-mTORC1/beta-catenin signaling and repressing HIF1AN-NOTCH2 signaling to increase C-MYC and SURVIVIN expression.
Biological pathway or process:

PI3K/AKT (promotes); PI3K/AKT/mTOR (promotes); Wnt/beta-catenin (promotes); Notch (inhibits); proliferation (promotes); apoptosis (inhibits); stemness (promotes); drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (promotes); other pathway/process (promotes)
Detected method:
Q
M
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Co-IP; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; IHC (Immunohistochemistry); ELISA; Western Blot; ROC Analysis; Bioinformatics Analysis
Clinical significance:

Circ-CDYL expression, alone or combined with HDGF and HIF1AN, was reported as an independent marker for discrimination/surveillance of early HCC; combined analysis achieved AUC 0.73 with sensitivity 75.36% and specificity 66.67%.
Description:

Circ-CDYL is a human CDYL-derived circRNA specifically upregulated in early-stage HCC. It functions as a ceRNA sponge for miR-892a and miR-328-3p to regulate HDGF and HIF1AN, driving PI3K-AKT-mTORC1/beta-catenin and HIF1AN-NOTCH2-related signaling changes that promote EPCAM-positive tumor-initiating properties, proliferation, chemoresistance, and tumor growth. Clinically, Circ-CDYL alone or combined with HDGF and HIF1AN was proposed as a biomarker for early HCC discrimination/surveillance.
Confidence score:

0.8892
Other information
Title:

A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: 2020
PubMed ID: 31148183
Study type:

combined biological and clinical study
Data availability: GSE121815
Code availability: -